{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:16Z","timestamp":1783075936264,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00406-021-01257-9","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:02:39Z","timestamp":1617667359000},"page":"1437-1443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Piacentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Endres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Paulzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"issue":"5","key":"1257_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/YIC.0000000000000131","volume":"31","author":"G Schoretsanitis","year":"2016","unstructured":"Schoretsanitis G, Haen E, Hiemke C, Grunder G, Stegmann B, Schruers KR, Veselinovic T, Lammertz SE, Paulzen M (2016) Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations? Int Clin Psychopharmacol 31(5):259\u2013264","journal-title":"Int Clin Psychopharmacol"},{"key":"1257_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00228-016-2085-2","volume":"72","author":"G Schoretsanitis","year":"2016","unstructured":"Schoretsanitis G, Stegmann B, Hiemke C, Gr\u00fcnder G, Schruers K, Walther S, Lammertz S, Haen E, Paulzen M (2016) Pharmacokinetic patterns of risperidone\u2014associated adverse drug reactions. Eur J Clin Pharmacol 72:1091\u20131098","journal-title":"Eur J Clin Pharmacol"},{"key":"1257_CR3","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1080\/17512433.2018.1549489","volume":"11","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, Spina E, Hiemke C, de Leon J (2018) A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol 11:1237\u20131253","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1257_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1177\/0269881116650390","volume":"30","author":"M Paulzen","year":"2016","unstructured":"Paulzen M, Haen E, Gr\u00fcnder G, Stegmann B, Schruers KJR, Walther S, Lammertz S, Schoretsanitis G (2016) Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients\u2014thinking of clinically relevant CYP2D6 interactions. J Psychopharmacology 30:803\u2013809","journal-title":"J Psychopharmacology"},{"key":"1257_CR5","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/17512433.2017.1345623","volume":"10","author":"G Schoretsanitis","year":"2017","unstructured":"Schoretsanitis G, Spina E, Hiemke C, de Leon J (2017) A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol 10:965\u2013981","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1257_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/17512433.2018.1478727","volume":"11","author":"G Schoretsanitis","year":"2018","unstructured":"Schoretsanitis G, Spina E, Hiemke C, de Leon J (2018) A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol 11:625\u2013639","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1257_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40268-015-0092-x","volume":"15","author":"M Corena-McLeod","year":"2015","unstructured":"Corena-McLeod M (2015) Comparative pharmacology of risperidone and paliperidone. Drugs R D 15:163\u2013174","journal-title":"Drugs R D"},{"key":"1257_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00213-007-1029-z","volume":"197","author":"R Arakawa","year":"2008","unstructured":"Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T (2008) Dose-finding study of paliperidone er based on striatal and extrastriatal dopamine d2 receptor occupancy in patients with schizophrenia. Psychopharmacology 197:229\u2013235","journal-title":"Psychopharmacology"},{"key":"1257_CR9","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/bcp.13050","volume":"82","author":"MN Samtani","year":"2016","unstructured":"Samtani MN, Nandy P, Ravenstijn P, Remmerie B, Vermeulen A, Russu A, D\u2019Hoore P, Baum EZ, Savitz A, Gopal S, Hough D (2016) Prospective dose selection and acceleration of paliperidone palmitate 3\u00a0month formulation development using a pharmacometric bridging strategy. Br J Clin Pharmacol 82:1364\u20131370","journal-title":"Br J Clin Pharmacol"},{"key":"1257_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1124\/dmd.107.018275","volume":"36","author":"M Vermeir","year":"2008","unstructured":"Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, Talluri K, Boom S, Eerdekens M, van Osselaer N, Cleton A (2008) Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 36:769\u2013779","journal-title":"Drug Metab Dispos"},{"key":"1257_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mossner R, Muller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:9\u201362","journal-title":"Pharmacopsychiatry"},{"key":"1257_CR12","first-page":"19cs13169","volume":"81","author":"Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Grunder G, American Society of Clinical P, Pharmakopsychiatrie T","year":"2020","unstructured":"Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Grunder G, American Society of Clinical P, Pharmakopsychiatrie T (2020) Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the american society of clinical psychopharmacology and the therapeutic drug monitoring task force of the arbeitsgemeinschaft fur neuropsychopharmakologie und pharmakopsychiatrie. J Clin Psychiatry 81:19cs13169","journal-title":"J Clin Psychiatry"},{"key":"1257_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/psp4.12217","volume":"6","author":"J Korell","year":"2017","unstructured":"Korell J, Green B, Remmerie B, Vermeulen A (2017) Determination of plasma concentration reference ranges for risperidone and paliperidone. CPT Pharmacomet Syst Pharmacol 6:589\u2013595","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1257_CR14","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1017\/S1461145709990988","volume":"13","author":"M Kramer","year":"2010","unstructured":"Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M (2010) Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 13:635\u2013647","journal-title":"Int J Neuropsychopharmacol"},{"key":"1257_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/hup.2388","volume":"29","author":"T Si","year":"2014","unstructured":"Si T, Su Y, Liu Y, Zhang H, Li H, Rui Q, Shu L (2014) Pharmacokinetics and tolerability of paliperidone palmitate injection in chinese subjects. Hum Psychopharmacol 29:203\u2013210","journal-title":"Hum Psychopharmacol"},{"key":"1257_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/s-0037-1601396","volume":"50","author":"MC Mauri","year":"2017","unstructured":"Mauri MC, Paletta S, Di Pace C, Reggiori A, Rovera C, Fiorentini A, Altamura CA (2017) Paliperidone long-acting plasma level monitoring and a new method of evaluation of clinical stability. Pharmacopsychiatry 50:145\u2013151","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"1257_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/a-1113-7862","volume":"53","author":"MC Mauri","year":"2020","unstructured":"Mauri MC, Reggiori A, Minutillo A, Franco G, Pace CD, Paletta S, Cattaneo D (2020) Paliperidone lai and aripiprazole lai plasma level monitoring in the prophylaxis of bipolar disorder type i with manic predominance. Pharmacopsychiatry 53(5):209\u2013219","journal-title":"Pharmacopsychiatry"},{"key":"1257_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.schres.2016.09.014","volume":"178","author":"H Verdoux","year":"2016","unstructured":"Verdoux H, Pambrun E, Tournier M, Bezin J, Pariente A (2016) Antipsychotic long-acting injections: a community-based study from 2007 to 2014 of prescribing trends and characteristics associated with initiation. Schizophr Res 178:58\u201363","journal-title":"Schizophr Res"},{"key":"1257_CR19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000135641","volume":"57","author":"Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE, Working Group \u2018Drugs in P\u2019","year":"2008","unstructured":"Fischer-Barnicol D, Lanquillon S, Haen E, Zofel P, Koch HJ, Dose M, Klein HE, Working Group \u2018Drugs in P\u2019 (2008) Typical and atypical antipsychotics\u2014the misleading dichotomy. Results from the working group \u2018drugs in psychiatry\u2019 (agate). Neuropsychobiology 57:80\u201387","journal-title":"Neuropsychobiology"},{"key":"1257_CR20","unstructured":"US Food and Drug Administration (FDA) (2014) Drug development and drug interactions: table of substrates, inhibitors and inducers. [Last accessed 16\/07\/2020]."},{"key":"1257_CR21","volume-title":"ECDEU assessment manual for psychopharmacology, revised","author":"W Guy","year":"1976","unstructured":"Guy W (1976) ECDEU assessment manual for psychopharmacology, revised. Publ No ADM 76-338 National Institute of Mental Health, Rockville"},{"key":"1257_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1055\/s-2005-862617","volume":"38","author":"W Bader","year":"2005","unstructured":"Bader W, Melchner D, Nonenmacher T, Haen E (2005) Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (hplc) and electrochemical detection. Pharmacopsychiatry 38:4","journal-title":"Pharmacopsychiatry"},{"key":"1257_CR23","first-page":"142","volume":"76","author":"L Paul","year":"2009","unstructured":"Paul L, Musshoff F, Aebi B, Auw\u00e4rter V, Kr\u00e4mer T, Peters F, Skopp G, Aderjan R, Herbold M, Schmitt G (2009) Richtlinie der gtfch zur qualit\u00e4tssicherung bei forensisch-toxikologischen untersuchungen. Toxichem Krimtech 76:142\u2013176","journal-title":"Toxichem Krimtech"},{"key":"1257_CR24","unstructured":"US Food and Drug Administration (FDA) (2001) Guidance for industry on biomedical method validation. [Last accessed 16\/07\/2020]."},{"key":"1257_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/FTD.0000000000000582","volume":"41","author":"C Hiemke","year":"2019","unstructured":"Hiemke C (2019) Concentration-effect relationships of psychoactive drugs and the problem to calculate therapeutic reference ranges. Ther Drug Monit 41:174\u2013179","journal-title":"Ther Drug Monit"},{"key":"1257_CR26","first-page":"31","volume":"54","author":"G Schoretsanitis","year":"2020","unstructured":"Schoretsanitis G, Haen E, Conca A, Piacentino D, Ridders F, Hiemke C, Gr\u00fcnder G, Paulzen M (2020) Lack of smoking effects on pharmacokinetics of oral paliperidone-analysis of a naturalistic therapeutic drug monitoring sample. Pharmacopsychiatry 54:31\u201335","journal-title":"Pharmacopsychiatry"},{"key":"1257_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00702-018-1953-6","volume":"126","author":"YA Su","year":"2019","unstructured":"Su YA, Bousman C, Li Q, Li JT, Lin JY, Si TM (2019) Genetic variations in the adck1 gene predict paliperidone palmitate efficacy in han chinese patients with schizophrenia. J Neural Transm (Vienna) 126:19\u201325","journal-title":"J Neural Transm (Vienna)"},{"key":"1257_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/FTD.0000000000000830","volume":"43","author":"G Schoretsanitis","year":"2020","unstructured":"Schoretsanitis G, Baumann P, Conca A, Dietmaier O, Giupponi G, Gr\u00fcnder G, Hahn M, Hart M, Havemann-Reinecke U, Hefner G, Kuzin M, M\u00f6ssner R, Piacentino D, Steimer W, Zernig G, Hiemke C (2020) Therapeutic drug monitoring of long-acting injectable antipsychotic drugs. Ther Drug Monit 43:79\u2013102","journal-title":"Ther Drug Monit"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-021-01257-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-021-01257-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-021-01257-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T12:10:40Z","timestamp":1635855040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-021-01257-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1007\/s00406-021-01257-9","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Haen received speaker\u2019s or consultancy fees from the following pharmaceutical companies: Servier, Novartis, and Janssen-Cilag. He is managing director of AGATE. He reports no conflict of interest with this publication. Dr. Hiemke has received speaker\u2019s or consultancy fees from Janssen-Cilag, Lohmann Transdermal Systems and Servier. He reports no conflict of interest with this publication. Dr. Conca has served as a consultant for Lilly, Bristol-Myers Squibb, and Pfizer. He has served on the speakers\u2019 bureau of Lilly, BMS, Astra Zeneca, Lundbeck, Italfarma, and Janssen. Dr. Gr\u00fcnder has served as consultant and advisory board member for the following companies and institutions: Allergan, Boehringer Ingelheim, Eli Lilly, IQWiG, Janssen-Cilag, Lundbeck, Otsuka, Recordati, SAGE and Takeda. He has received honoraria as a speaker for Gedeon-Richter, Janssen-Cilag, Lundbeck, Neuraxpharma, Otsuka and Recordati and funding for clinical trials from Boehringer Ingelheim, Lundbeck and Saladax. He is the founder and Shareholder of Brainfoods GmbH and Mind and Brain Institute GmbH. Dr. Paulzen has received speaker\u2019s fees from Neuraxpharm, Lundbeck and Otsuka. He reports no conflict of interest with this publication. All other authors report no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data are available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}